Table 3: Stroke.

In this table, all pre-clinical studies from 2004 to 2018 which focused on stem cell therapy for stroke are referenced. Moreover, the clinical trials presented were selected due to their 1) recency and 2) availability of published results. In summary, pre-clinical investigation in animal models of stroke show that treatment with various stem cell types improved sensorimotor functioning and reduced infarct volume. In humans, stem cell treatment was shown to be safe and effective in improving left ventricular function and NIHSS scores in stroke patients.

Author	Model	Cell type	Cell Quantity	Outcomes
Borlongan et al., 2010	MCAO	Menstrual blood cells	4×105 cells	Sensorimotor improvement
Kurozumi et al., 2005	MCAO	Human BM-MSC	5 × 105 cells	Reduction of infarct-volume and Sensorimotor improvement
Fukuda et al., 2004	MCAO	Human BM-MSC	low-dose 1 × 106 cells high-dose 6 × 106 cells	Sensorimotor improvement
Borlongan et al., 2004c	MCAO	CP cells	50–55 microcapsules	Sensorimotor improvement
Hara et al., 2007	MCAO	NT2N cells	2× 105 cells	Sensorimotor improvement
Tajiri, et al., 2012	MCAO	human NSCs	5 × 103 cells 1 × 104 cells 2 × 104 cells	Reduction of infarct-volume and Sensorimotor improvement
Borlongan et al., 2005	MCAO	human bone-marrow-derived CD133+ cells	1 × 104 cells	Sensorimotor improvement
Nelson et al., 2002	Human Stroke Patients	human NT2N	2 × 106 cells	Safe (no adverse effects)
Bang et al., 2016	Human Stroke Patients	MSC	1 × 108 cells	improved left ventricular function
Kalladka et al., 2016	Human Stroke Patients	Human neural stem cells 2 × 106 Intracerebral	Human neural stem cells 2 × 106 Intracerebral	improvement in NIHSS score

BM-MSCs – bone marrow-derived mesenchymal stem cells; MCAO – middle cerebral artery occlusion; NT2N - Ntera2/D1 neuron-like; NIHSS – National Institutes of Health Stroke Scale; NSC – neural stem cells; CP – choroid plexus